Aristides Capital’s Avita Medical RCEL Stock Holding History

Aristides Capital’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,900	Closed	-$48K	–	257
2025 Q4	$48K	Buy	+13,900	New	+$55.5K	0.01%	262

Other funds holding RCEL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Aristides Capital's RCEL Position: Q1 2026 in Review

Aristides Capital sold out of Avita Medical (RCEL) in Q1 2026, closing a stake of 13,900 shares — an estimated $48K sold.

Aristides Capital first reported a position in RCEL in Q4 2025 and held it in 1 quarter. The position peaked at $48K in Q4 2025. 79 funds tracked by Wall St. Rank hold RCEL as of Q1 2026.

Aristides Capital reported no remaining Avita Medical position as of Q1 2026 after selling out during the quarter.
Aristides Capital sold 13,900 Avita Medical shares in Q1 2026, an estimated $48K.
Aristides Capital first reported a position in Avita Medical in Q4 2025 and held it in 1 quarter.
Aristides Capital's Avita Medical position peaked at $48K in Q4 2025.
79 funds tracked by Wall St. Rank held Avita Medical as of Q1 2026.

Based on Aristides Capital's 13F filing for Q1 2026, filed 14 May 2026.